CNTA CENTESSA PHARMACEUTICALS PLC

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, Nov. 07, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:

Event: Guggenheim 2nd Annual Healthcare Innovation Conference

Date: Wednesday, November 12, 2025

Fireside Chat: 10:30 AM ET

Event: Jefferies Global Healthcare Conference in London

Date: Tuesday, November 18, 2025

Fireside Chat: 2:00 PM GMT/ 9:00 AM ET

Event: 37th Annual Piper Sandler Healthcare Conference

Date: Tuesday, December 2, 2025

Fireside Chat: 3:00 PM ET

Event: 8th Annual Evercore Healthcare Conference

Date: Wednesday, December 3, 2025

Fireside Chat: 9:35 AM ET

Event: Oppenheimer Movers in Rare Disease Summit

Date: Thursday, December 11, 2025

Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at .

About Centessa Pharmaceuticals

Centessa Pharmaceuticals, plc is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients. We are pioneering a new class of potential therapies within our orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, and fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. For more information, visit , which does not form part of this release.

Contact:

Kristen K. Sheppard, Esq.

SVP of Investor Relations



EN
07/11/2025

Underlying

CNTACENTESSA PHARMACEUTICALS PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CENTESSA PHARMACEUTICALS PLC

 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offe...

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced the pricing of an underwritten public offering of 11,627,907 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $21.50 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $250 million, before deducting underwriting discounts and comm...

November 12, 2025 1 EN
 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals Announces Proposed Public Offering of America...

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ADSs offered in the public offering. The proposed offeri...

November 11, 2025 1 EN
 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferenc...

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences BOSTON and LONDON, Nov. 07, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim 2nd Annual Healthcare Innovation ConferenceDate: Wednesday, November 12, 2025Fireside Chat: 10:30 AM ET Event: Jefferies Global Healthcare Conference in LondonDate: Tuesday, November 18, 2025Fireside Chat: 2:0...

November 7, 2025 1 EN
 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals Reports Financial Results for the Third Quart...

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program ORX750: Demonstrated potential best-in-class profile for treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) in initial cohorts of ongoing Phase 2a study; Data mark first robust demonstration of oral OX2R agonist addressing wakefulness needs of patients across all three indications; Expect to initiate registrational program in Q1 2026ORX142: Phase 1 data support highly differentiate...

November 5, 2025 1 EN
 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Ann...

Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. A fireside chat is scheduled for Tuesday, September 9th at 4:50 PM ET. The live audio webcast of this event, as well as an archived recording, will be avail...

September 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch